A5085006885- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- Cancer, Lipids, and Metabolism
- Ubiquitin and proteasome pathways
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- 3D Printing in Biomedical Research
- Organ Transplantation Techniques and Outcomes
- Cancer Mechanisms and Therapy
- Cancer-related molecular mechanisms research
- Cancer Cells and Metastasis
- Voice and Speech Disorders
- Genetic factors in colorectal cancer
- Cancer-related gene regulation
- Thyroid and Parathyroid Surgery
- Epigenetics and DNA Methylation
- Head and Neck Anomalies
- Advanced biosensing and bioanalysis techniques
- Airway Management and Intubation Techniques
- Immune cells in cancer
- Cancer-related Molecular Pathways
- Liver physiology and pathology
Xiangya Hospital Central South University
2012-2024
Central South University
2014-2024
Sun Yat-sen University
2022
Sun Yat-sen University Cancer Center
2022
Zhejiang University
2022
Cornell University
2015
Houston Methodist
2014-2015
Operation PAR
2005
Abstract Radiofrequency ablation (RFA) promotes tumor antigen-specific T cell responses and enhances the effect of immunotherapy in preclinical settings. Here we report that existence remnant masses due to incomplete RFA (iRFA) is associated with earlier new metastases poor survival patients colorectal cancer liver (CRCLM). Using mouse models, demonstrate iRFA progression hinders efficacy anti-PD-1 therapy. Immune analysis reveals induces sustained local inflammation predominant myeloid...
Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, the fourth most common malignancy and second leading cause tumor-related death, thereby posing a significant threat to life health Chinese people.Since publication Guidelines for Diagnosis Treatment Liver Cancer China June 2017, were updated by National Health Commission December 2019, additional high-quality evidence has emerged from researchers worldwide regarding diagnosis, staging, treatment that requires...
Systemic nutrition and inflammation are the critical factors in cancer initiation, evolution, progression. This study aimed to evaluate prognostic value of nutritional index (PNI) systemic immune-inflammation (SII) hepatocellular carcinoma (HCC) patients who underwent liver resection. A total 202 HCC met criteria were included study. The receiver operating characteristic (ROC) curve was used calculate optimal PNI SII cutoff values. relationship between PNI/SII clinicopathologic parameters...
Hepatocellular carcinoma (HCC) is a lethal and aggressive human malignancy. The present study examins the anti-tumor effects of deubiquitylating enzymes (DUB) inhibitors in HCC. It found that inhibitor ubiquitin specific peptidase 8 (USP8) DUB-IN-3 shows most effective anti-cancer responses. Targeting USP8 inhibits proliferation HCC induces cell ferroptosis. In vivo xenograft metastasis experiments indicate inhibition suppresses tumor growth lung metastasis. treatment or depletion decrease...
Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer in adults. Previous studies our laboratory found that long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) was upregulated HCC cells, which could affect metastasis and invasion of HCC. However, underlying mechanism remains unknown. Herein, we studied interaction between MALAT1 miR-140 on regulation angiogenesis immunosuppressive properties. We revealed expression VEGF-A significantly...
Abstract Hepatocellular carcinoma (HCC) is the most common type of primary hepatic carcinoma, which a growing public health problem worldwide. One main genetic alterations in HCC deregulated Wnt/β-catenin signaling, activation β-catenin associated with progression HCC. In present study, we aimed to identify novel modulators controlling ubiquitination and stability. USP8 was overexpressed tissues correlated protein level. High expression indicated poor prognosis patients. depletion...
Increasing evidence supports the significance of long non-coding RNA in cancer development. Several recent studies suggest oncogenic activity metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) hepatocellular carcinoma. In this study, we explored molecular mechanisms by which MALAT1 modulates carcinoma biological behaviors. We found that microRNA-204 was significantly downregulated sh-MALAT1 HepG2 cell and 15 tissues quantitative real-time polymerase chain reaction analysis....
Abstract The extensive phenotypic and functional heterogeneity of cancer cells plays an important role in tumor progression therapeutic resistance. Characterizing this identifying invasive phenotype may provide possibility to improve chemotherapy treatment. By mimicking cell perfusion through circulatory system metastasis, we develop a unique microfluidic cytometry (MC) platform separate at high throughput further derive physical parameter ‘transportability’ characterize the ability pass...
Hepatocellular carcinoma (HCC) is an aggressive and heterogeneous disease characterized by high morbidity mortality. The liver the vital organ that participates in tyrosine catabolism, abnormal metabolism could cause various diseases, including HCC. Besides, tumor immune microenvironment involved carcinogenesis can influence patients' clinical outcomes. However, potential role of pattern molecular signature poorly understood HCC.Gene expression, somatic mutations, copy number variation data,...
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal human malignancies, with quite limited treatment alternatives. The proteasome responsible for protein degradation in eukaryotic cells required maintenance intracellular homeostasis. However, its potential role HCC largely unknown. In current study, we identified translation initiation factor 3 subunit H (EIF3H), belonging to JAB1/MPN/MOV34 (JAMM) superfamily, as a bona fide deubiquitylase O-GlcNAc transferase (OGT) HCC....
Lenvatinib plus an anti-PD-1 antibody has shown promising antitumor effects in patients with advanced hepatocellular carcinoma (HCC), but clinical benefit limited to a subset of patients. We developed and validated radiomic-based model predict objective response this combination therapy HCC
Chemotaxis is the phenomenon by which migration and invasion of cells directed in response to an extracellular chemical gradient. tumor tumor-associated inflammatory stromal mediated chemokines, chemokine receptors, growth factors, factor receptors. Current techniques used study chemotactic driven cell metastasis utilize two-dimensional assays involving imaging analyzing on glass slides or plastic surfaces, requires large numbers often lacks real-time monitoring vertical movement...
Abstract Background Pathologic complete response (pCR) following preoperative systemic therapy is associated with improved outcomes after subsequent liver transplant/resection in hepatocellular carcinoma (HCC). However, the relationship between radiographic and histopathological remains unclear. Methods We retrospectively examined patients initially unresectable HCC who received tyrosine kinase inhibitor (TKI) plus anti–programmed death 1 (PD-1) before undergoing resection March 2019...
Majority of patients with resected early- and intermediate-stage liver cancer will experience postoperative recurrence. This study aimed to investigate the application ctDNA sequencing in period hepatocellular carcinoma. A total 96 were enrolled this study. Postoperative peripheral blood samples collected from all after surgery analyzed using hybridization capture-based next-generation sequencing. Identification at least one somatic mutation was defined as ctDNA+. Five genetic features tumor...
Systemic therapy is the standard care of unresectable hepatocellular carcinoma (uHCC), while transcatheter intra-arterial therapies (TRITs) were also widely applied to uHCC patients in Chinese practice. However, benefit additional TRIT these unclear. This study investigated survival concurrent and systemic used as first-line treatment for with uHCC.
Abstract Background The difference in the prognoses between treatment with surgical therapy and continuation of local-plus-systemic following successful down-staging intermediate-advanced hepatocellular carcinoma (HCC) remains unclear. Methods Data 405 patients HCC treated at 30 hospitals across China from January 2017 to July 2022 were retrospectively reviewed. All received divided into (n = 100) nonsurgical groups 305) according whether they therapy. differences long-term 2 compared....
Oxaliplatin (OXA) resistance is a major clinic challenge in hepatocellular carcinoma (HCC). Ferroptosis kind of iron-dependent cell death. Triggering ferroptosis considered to restore sensitivity chemotherapy. In the present study, we found that USP20 was overexpressed OXA-resistant HCC cells. High expression associated with poor prognosis. contributes OXA and suppress HCC. Pharmacological inhibition or knockdown triggered increased cells both vitro vivo. Coimmunoprecipitation results...